{"organizations": [], "uuid": "2e1fc6520daa6c93b9ea897061be500f461db666", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180419.html", "section_title": "Archive News &amp; Video for Thursday, 19 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-paxman-receives-market-approval-in/brief-paxman-receives-market-approval-in-mexico-idUSFWN1RW0J5", "country": "US", "domain_rank": 408, "title": "BRIEF-Paxman Receives Market Approval In Mexico", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.999, "site_type": "news", "published": "2018-04-19T20:02:00.000+03:00", "replies_count": 0, "uuid": "2e1fc6520daa6c93b9ea897061be500f461db666"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-paxman-receives-market-approval-in/brief-paxman-receives-market-approval-in-mexico-idUSFWN1RW0J5", "ord_in_thread": 0, "title": "BRIEF-Paxman Receives Market Approval In Mexico", "locations": [], "entities": {"persons": [{"name": "laun", "sentiment": "negative"}, {"name": "paxman", "sentiment": "negative"}], "locations": [{"name": "mexico", "sentiment": "none"}, {"name": "mexico", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "teva", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 19 (Reuters) - PAXMAN AB (PUBL):\n* PAXMAN RECEIVES MARKET APPROVAL IN MEXICO AND PLANS Q2 LAUNCH WITH LICENSE PARTNER TEVA PHARMACEUTICAL INDUSTRIES LTD\n* RECEIVED MARKET APPROVAL IN MEXICO FOR ITS SCALP COOLING SYSTEM\n* “WE CAN LAUNCH PRODUCT OFFICIALLY ALREADY IN Q2 OF 2018”\n* LICENSE AGREEMENT WITH TEVA WILL GENERATE ONGOING REVENUES BASED ON EVERY COLD CAP OR TREATMENT SOLD Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-19T20:02:00.000+03:00", "crawled": "2018-04-20T12:10:55.156+03:00", "highlightTitle": ""}